SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

SABS

SAB Biotherapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Traders should anticipate near-term downward pressure on the stock due to dilution; monitor for insider selling or short interest changes. The capital raise extends the runway for SAB-142 development, but lack of near-term catalysts may limit upside until clinical data releases.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.70
T+0 close · Mar 17, 2026 · via day close
Latest settled
−8.65%
T+60 · $3.38
Vs SPY
−20.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $3.70entry
  2. T+1 · 8mo ago +2.16%α +2.43% · $3.78
  3. T+5 · 8mo ago +3.24%α +3.96% · $3.82
  4. T+20 · 7mo ago +5.95%α −0.10% · $3.92
  5. T+60 · 5mo ago −8.65%α −20.17% · $3.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-funded warrants for 2.8 million shares at $3.8499, raising approximately $85 million in gross proceeds. The funds will primarily support clinical development of its lead candidate, SAB-142, for type 1 diabetes. The offering includes a 30-day underwriter option to purchase up to an additional 3.3 million shares.

Key Financial Metrics

Deal Value
$85.0M

Key Facts

  • SAB Biotherapeutics is raising approximately $85 million through a public offering of common stock and pre-funded warrants.
  • 19,324,677 shares priced at $3.85 per share; pre-funded warrants for 2,753,246 shares priced at $3.8499.
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
  • Proceeds will fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.
  • The offering is expected to close on or about March 19, 2026, subject to customary conditions.

Financial Impact

$85 million gross proceeds, with significant dilution from ~19.3M new shares and ~2.8M pre-funded warrants; underwriters may add ~3.3M more shares.

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from issuance of over 22 million shares (including warrants and potential over-allotment).
  • Biotech clinical-stage risk: SAB-142 is still in Phase 2b with no guarantee of success.
  • Market conditions could delay or alter the final closing terms, though pricing is already set.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257861

Track record

15 reports on SABS

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026